Worked example

What an HDDT output looks like

A fully anonymized walk-through of how HDDT reads an opportunity — from tested thesis to a published authority-page preview.

Scope your own HDDT See the method

ExampleCo Therapeutics

Extracellular vesicle anti-inflammatory platform

ExampleCo Therapeutics is a fictional company used to illustrate HDDT output. All evidence, scores, and interpretations below are illustrative and do not describe any real company or dataset.

Tested thesis

The claim under test

ExampleCo's engineered extracellular vesicle platform can deliver an anti-inflammatory payload with a better therapeutic index than conventional particles, in an indication where the preclinical model is relevant and a credible next financing exists.

Hypothesis table

Each claim, tested and scored

The thesis is decomposed into five hypotheses. Each is graded on the evidence for and against it, with the investor implication stated plainly.

Hypothesis	Evidence support	Evidence against / uncertainty	Confidence	Investor implication
The platform has a plausible biological mechanism.	Mechanism is consistent with published extracellular vesicle biology and prior anti-inflammatory cargo work.	Mechanistic support is largely in vitro; causal in vivo confirmation in the target tissue is limited.	Moderate	Plausible enough to justify diligence, but mechanism is not yet independently de-risked.
The delivery modality improves therapeutic index over conventional particles.	Early comparisons suggest improved tolerability at comparable exposure in a single model.	No head-to-head dose-ranging against a modern comparator; therapeutic index claim rests on limited data.	Weak	Central differentiation claim is under-evidenced and should be a priority diligence question.
The preclinical model is relevant to the proposed indication.	The chosen model is used in the field and captures a key inflammatory axis of the indication.	Model has known translational gaps; several comparators that succeeded here failed later in humans.	Contradicted	Historical failures in this model temper confidence; translational risk is material.
The company has a credible next financing milestone.	Proposed milestone (IND-enabling package) is standard and fundable in the category.	Budget-to-milestone assumptions appear optimistic relative to comparable programs.	Moderate	Milestone is the right shape; capital efficiency assumptions need scrutiny.
The investor narrative is differentiated from prior failed comparators.	Team articulates specific engineering differences versus earlier platforms.	Several differences are not yet tied to measured outcomes, so differentiation is largely narrative.	Unresolved	Differentiation is stated but not yet demonstrated; evidence must catch up to the story.

The platform has a plausible biological mechanism.

Moderate

Evidence support: Mechanism is consistent with published extracellular vesicle biology and prior anti-inflammatory cargo work.
Evidence against / uncertainty: Mechanistic support is largely in vitro; causal in vivo confirmation in the target tissue is limited.
Investor implication: Plausible enough to justify diligence, but mechanism is not yet independently de-risked.

The delivery modality improves therapeutic index over conventional particles.

Weak

Evidence support: Early comparisons suggest improved tolerability at comparable exposure in a single model.
Evidence against / uncertainty: No head-to-head dose-ranging against a modern comparator; therapeutic index claim rests on limited data.
Investor implication: Central differentiation claim is under-evidenced and should be a priority diligence question.

The preclinical model is relevant to the proposed indication.

Contradicted

Evidence support: The chosen model is used in the field and captures a key inflammatory axis of the indication.
Evidence against / uncertainty: Model has known translational gaps; several comparators that succeeded here failed later in humans.
Investor implication: Historical failures in this model temper confidence; translational risk is material.

The company has a credible next financing milestone.

Moderate

Evidence support: Proposed milestone (IND-enabling package) is standard and fundable in the category.
Evidence against / uncertainty: Budget-to-milestone assumptions appear optimistic relative to comparable programs.
Investor implication: Milestone is the right shape; capital efficiency assumptions need scrutiny.

The investor narrative is differentiated from prior failed comparators.

Unresolved

Evidence support: Team articulates specific engineering differences versus earlier platforms.
Evidence against / uncertainty: Several differences are not yet tied to measured outcomes, so differentiation is largely narrative.
Investor implication: Differentiation is stated but not yet demonstrated; evidence must catch up to the story.

Evidence snapshot

Support / refute at a glance

Strongest support

The proposed mechanism is broadly consistent with published extracellular vesicle biology, and the next financing milestone is a standard, fundable shape for the category.

Weakest links

The core therapeutic-index differentiation rests on a single model with no modern head-to-head comparison. Differentiation from failed comparators is currently narrative rather than measured.

Overall read

Fundable to diligence, but the differentiation and translational claims must be strengthened before they support the valuation the narrative implies.

Composite confidence:Moderate

Key contradictions

What argues against the thesis

HDDT deliberately surfaces the counter-case. These are the points a skeptical investor would press on first.

The therapeutic-index advantage rests on a single model without modern head-to-head comparison.
The preclinical model has a track record of positive results that did not translate to humans.
Differentiation from failed comparators is currently narrative rather than data-backed.

Investor interpretation

What a careful reader would conclude

The science is plausible and the milestone is fundable, so the opportunity clears the bar for real diligence. But the two claims that most affect value — a better therapeutic index and genuine differentiation from prior failures — are the least supported.

Recommended posture: proceed to diligence with the therapeutic-index comparison and model-translatability questions as gating items.

Reminder

This interpretation structures the evidence. It does not make the investment decision, which remains with the investor.

Authority-page output

How the diligence gets published

The reviewed conclusion becomes a structured, citation-backed page — the same pattern this microsite uses.

bioticabio.com/authority/exampleco-therapeutics

Summary block (AI-readable)

ExampleCo Therapeutics is developing an extracellular vesicle anti-inflammatory platform. Independent HDDT testing finds the mechanism plausible and the next milestone fundable, with the therapeutic-index and differentiation claims currently under-evidenced.

Investor FAQ

What must be true for this to work?

Citation table

Every claim linked to its sources

Run this on your opportunity.

Get a structured, skeptical read you can act on — and publish.

Request an HDDT Snapshot See services